SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...

Almost every week, a young woman with breast cancer will tell Jennifer Tseng, MD, FACS, she wants a mastectomy because of her ...

Efficacy of neoadjuvant/induction (NAC) chemotherapy in nonmetastatic muscle-invasive bladder cancer treated with chemoradiotherapy (CRT): A systematic review and meta-analysis. This is an ASCO ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, ...

Neoadjuvant radiotherapy followed by surgery can improve overall survival compared with surgery alone in certain patients with locally advanced rectal cancers, most notably in those with lower rectal ...

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

Neoadjuvant immunotherapy is emerging as a valuable option for patients with complex or borderline resectable cutaneous squamous cell carcinoma (CSCC). Administered before surgery, PD-1 inhibitors ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Neoadjuvant approaches for HER2-positive breast cancer continue ...

Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...